Laura Biganzoli
Hospital of Prato · USL4 Hospital of Prato, Italy · Azienda USL 4 Prato
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Laura Biganzoli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06363812 · Probability of OncotypeDx to Reallocate As Low or High Risk of Recurrence Breast Cancer Patients with Uncertain BiologyFondazione Sandro Pitigliani · completed · Breast Cancer · principal investigator
- Ph2NCT03944434 · FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerFondazione Sandro Pitigliani · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT03644186 · To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)ETOP IBCSG Partners Foundation · completed · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer · study chair
- N/ANCT02785887 · Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology PatientsAzienda USL 4 Prato · completed · Breast Cancer, Lung Cancer, Ovarian Cancer · principal investigator
- Ph2NCT02783222 · EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT CancerFondazione Sandro Pitigliani · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:54 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.N Engl J Med · 2024478 citationsRCR 61.6
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.Lancet Oncol · 2019401 citationsRCR 13.5
- 291 citationsRCR 6.2
- 176 citationsRCR 3.8
- 175 citationsRCR 3.5
- Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.Eur J Cancer · 2004133 citationsRCR 3.5
- Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.J Clin Oncol · 1996118 citationsRCR 4.0
- Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.Clin Cancer Res · 202098 citationsRCR 3.5
- 89 citationsRCR 2.2
- Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.Breast Cancer Res Treat · 201289 citationsRCR 2.1